Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream
Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Inc. (ARQT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 11,535,582 | $161,728,860 | +1% | 4.88% |
| 2. | Rubric Capital Management David Rosen | 10,749,457 | $150,707,387 | -2% | 2.28% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 5,006,475 | $70,190,780 | -26% | 0.37% |
| 4. | D E Shaw D. E. Shaw | 2,163,001 | $30,325,274 | +9% | 0.02% |
| 5. | Point72 Asset Management Steve Cohen | 1,485,425 | $20,825,659 | +79% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.08 | 2,646 | $34,610.47 | 27,448 | 2025-06-13 | Filing | |
| $13.41 | 378 | $5,069.28 | 24,802 | 2025-06-05 | Filing | |
| $13.32 | 1,890 | $25,177.45 | 24,424 | 2025-06-04 | Filing | |
| $13.65 | 2,520 | $34,398.00 | 22,534 | 2025-05-22 | Filing | |
| $13.66 | 2,520 | $34,423.20 | 20,014 | 2025-05-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.52 | 504 | $8,829.02 | 891,440 | 2025-09-09 | Filing | |
| $17.54 | 9,625 | $168,799.40 | 891,944 | 2025-09-08 | Filing | |
| $16.16 | 36,130 | $583,716.28 | 161,234 | 2025-09-04 | Filing | |
| $15.64 | 10,000 | $156,383.00 | 100,206 | 2025-09-02 | Filing | |
| $15.57 | 2,438 | $37,968.92 | 104,811 | 2025-08-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,109,405 | $155,753,857 | 0.09% | |
| 2. | 9,874,511 | $138,440,644 | 5.54% | |
| 3. | 8,532,761 | $119,629,310 | 0% | |
| 4. | 7,049,099 | $98,828,368 | 0% | |
| 5. | 4,526,937 | $63,467,657 | 0% |
News See All
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 14 Best Small Cap Stocks to Buy Right Now. On September 3, Arcutis Biotherapeutics, Inc.
14 Best Small Cap Stocks to Buy Right Now
The S&P 600 and S&P BSE Small Cap indexes had soared 0.29% and 0.30%, respectively, while the Russell 2000 has jumped nearly 0.48% as of September 8. The U.S.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics 2025 Second Quarter Financial Results Conference Call.
Arcutis' ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, Arcutis Biotherapeutics Inc.
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current market conditions.
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc.
10 Best Small-Cap Growth Stocks to Buy According to Analysts
On March 26, Gabelli Funds released its small-cap 2025 outlook, highlighting the valuation discounts backing the small caps and the tailwinds from the macroeconomic backdrop.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript
Operator: Good day and welcome to Arcutis Biotherapeutics' 2025 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
